Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Taselisib plus fulvestrant shows encouraging results for advanced breast cancer

Dr. Joseph Delano Fule Robles
21 Jun 2018
Prof José Baselga. Photo by © ASCO/Brian Powers 2018.

The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.

In the randomized, double-blind, placebo-controlled phase III SANDPIPER trial, taselisib in combination with fulvestrant significantly improved investigator-assessed progression-free survival (PFS) among patients with PIK3CA mutation–positive advanced or metastatic breast cancer compared with placebo plus fulvestrant (median, 7.4 months vs 5.4 months; hazard ratio [HR], 0.70; p=0.0037). [Baselga J, ASCO 2018, abstract LBA 1006]

The combination therapy also demonstrated benefits over fulvestrant monotherapy in terms of objective response rate (ORR, 28 percent vs 11.9 percent; p=0,0002), clinical benefit rate (CBR, 51.5 percent vs 37.3 percent), and duration of objective response (DoR, 8.7 months vs 7.2 months). Overall survival (OS) data is still immature.

“This is proof that targeting the PI3K pathway has an effect in breast cancer. About 40 percent of all patients with ER-positive advanced breast cancer have PIK3CA mutations,” said lead investigator Professor José Baselga of the Memorial Sloan Kettering Cancer Center, New York, US.

“The benefit to patients, however, was more modest than we had hoped for, and there are considerable side effects that are associated with the addition of taselisib,” added Baselga.

The most common grade ≥3 adverse events (AEs) among patients who received one or more doses of taselisib plus fulvestrant were diarrhoea (12 percent), hyperglycaemia (10 percent), colitis (3 percent), and stomatitis (2 percent). The AEs led to more discontinuations of the treatment combination (17 percent vs 2 percent) and more dose reductions (37 percent vs 2 percent) as compared with placebo.

“It is encouraging to see a new therapy that can provide some benefits to women with advanced breast cancer. However, because the treatment has side effects, doctors will have to weigh its benefits and risks with their patients,” commented Dr Harold Burstein of the Dana Farber Cancer Institute, Boston, US.

The study enrolled a total of 516 postmenopausal patients with disease recurrence or progression during or after aromatase inhibitor therapy. The patients were randomized to receive oral taselisib 4 mg once daily or placebo in combination with fulvestrant 500 mg. Patients were stratified according to the presence of visceral disease, endocrine sensitivity, geographic region, and presence or absence of PIK3CA mutations.

Based on geographic stratification, the investigators noted that taselisib provided more benefit to study participants from North America and Europe as compared with patients from other countries, including Eastern Europe and Latin America where taselisib appeared to provide very little or no added benefit. Further studies are necessary to understand the reasons for this difference.

Taselisib is the first-of-its-kind inhibitor of the PI3K alpha isoform that is mutated in ER-positive breast cancers. Previous trials have shown its benefit in head and neck and gynaecologic cancers. [Mol Cancer Ther 2015;14:2519-2526; Clin Cancer Res 2016;22:2009-2019]
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.